2023 年第 11 期 第 18 卷

盐酸埃克替尼联合安罗替尼一线治疗晚期非小细胞肺癌效果以及安全性分析

Efficacy and safety analysis of icotinib hydrochloride combined with anlotinib in the first-line treatment of advanced non-small cell lung cancer

作者：曹冉华呼群

英文作者：Cao Ranhua Hu Qun

单位：内蒙古医科大学附属医院肿瘤内科，呼和浩特010050

英文单位：Department of Oncology the Affiliated Hospital of Inner Mongolia Medical University Hohhot 010050 China

关键词：非小细胞肺癌；盐酸埃克替尼；安罗替尼

英文关键词：Non-smallcelllungcancer;Icotinibhydrochloride;Anlotinib

• 摘要：

• 目的  探究盐酸埃克替尼联合安罗替尼一线治疗晚期非小细胞肺癌（NSCLC）的效果与安全性。方法  选取2018年1月至2019年9月在内蒙古医科大学附属医院接受一线治疗的100例晚期NSCLC患者，按照随机数字表法分为观察组和对照组，各50例。对照组口服盐酸埃克替尼治疗，观察组在对照组的基础上口服盐酸安罗替尼胶囊治疗。比较2组临床疗效、治疗前和治疗4个周期后健康相关生活质量（HRQol）、疾病相关症状以及体能状态评分，比较2组治疗期间不良事件发生率。结果  治疗4个周期后，观察组客观缓解率、疾病控制率均高于对照组［72.0%(36/50)比52.0%(26/50)、82.0%(41/50)比64.0%(32/50)］（均P＜0.05）。治疗4个周期后，2组躯体、角色、认知、情绪、社会功能评分和整体生命质量评分及恶心呕吐、便秘、腹泻、经济困难症状评分均高于治疗前，疲乏、疼痛、气促、失眠、食欲丧失症状评分及东部肿瘤协作组评分为2分的患者比例均低于治疗前（均P＜0.05）。2组治疗期间不良事件均为1～2级，组间各不良事件发生率比较差异均无统计学意义（均P＞0.05）。观察组无进展生存期、缓解持续时间、总生存期均长于对照组，1年及2年的总生存率均高于对照组（均P＜0.05）。结论  盐酸埃克替尼联合安罗替尼一线治疗晚期NSCLC的效果好，可改善患者生活质量与相关症状，且安全性较好。

• Objective  To explore the efficacy and safety of icotinib hydrochloride combined with anlotinib in the first-line treatment of advanced non-small cell lung cancer (NSCLC). Methods  Totally 100 patients with advanced NSCLC who received first-line treatment at the Affiliated Hospital of Inner Mongolia Medical University from January 2018 to September 2019 were selected. They were randomly divided into observation group and control group, with 50 patients in each group. The control group was treated with icotinib hydrocholride, while the observation group was treated with icotinib hydrochloride combined with arotinib. The clinical efficacy, health-related quality of life (HRQol), disease-related symptoms, and physical status scores between the two groups before and after 4 treatment cycles were compared, and the incidence of adverse events during the treatment period between the two groups were compared. Results  After 4 cycles of treatment, the Objective   response rate and disease control rate of the observation group were higher than those of the control group［72.0%(36/50) vs 52.0%(26/50), 82.0%(41/50) vs 64.0%(32/50)］(both P＜0.05). After 4 cycles of treatment, the physical, role, cognitive, emotional, social function scores, overall quality of life scores, and symptoms of nausea, vomiting, constipation, diarrhea, and economic difficulties scores of both groups were higher than before treatment, while symptoms of fatigue, pain, shortness of breath, insomnia, and loss of appetite scores and the proportion of patients with an Eastern Cooperative Oncology Group score of 2 were lower than those before treatment (all P＜0.05). During the treatment period, the adverse events of both groups were grade 1-2, and the incidences of adverse events between the two groups were similar (all P＞0.05). The progression free survival, response duration, and overall survival of the observation group were longer than those of the control group, and the overall survival rates at 1 and 2 years were higher than those of the control group (all P＜0.05). Conclusion  The application of icotinib hydrochloride combined with anlotinib in the first-line treatment of advanced NSCLC is effective. It can improve the quality of life and related symptoms of patients and has good safety.